Cumulative Event Rate
Figure 2a · Panel Figure_2a
Panel Figure_2a 是同一 Figure 2a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiao-Qiang Liu, Yang-Yang Qi, Tao Huang, Li-Li Huang, Ming-Xuan Zhao, Zhong-Fang Wang, Jun Dai, Yan-Xia Wang, Jing-Jing Chen, Xiao-Yun Yang, Hui-Lan Fan, Xue-Mei Yan, Jian-Chang He, Yan-Xiang Zou, Zhi-Wei Jiang, Zhi-Fei Zhan, Si-Wen Tao, De-Fang Dai, Feng Shi, Qiong-Na Zhang, Xiu-Liang Yang, Xiao-Zhong Li, Wei Li, Jing Lu, Jiang-Bing Zheng, Zhi-Hua Zhang, Gao-Xiang Chen, Hong Su, Wei-Min Gao, Lorenz von Seidlein, Xuan-Yi Wang, Lin Yuan, Jin-Zhong Lin
Hum Vaccin Immunother 21(1) 2502250
A randomized, double-blind, controlled phase 3 trial was conducted during a COVID-19 outbreak after the initial, stringent zero-Covid policy was relaxed in three provinces. Eligible adults aged ≥18 years who had received three doses of inactivated COVID-19 vaccines 6 months earlier were randomly assigned in a 1:1 ratio to receive either one intramuscular injection of RQ3013 or ZF2001 vaccine. The primary end point was protection against PCR-confirmed symptomatic SARS-CoV-2 infection with onset at least 7 days after the booster. A total of 3,167 and 3,169 eligible participants received one dose of RQ3013 or ZF2001 vaccine, respectively. COVID-19 illness was confirmed in 91 participants in the ZF2001 group (11.8 per 100 person years; 95% confidence interval [CI]: 9.6-14.6) and in 45 participants in the RQ3013 group (5.7 per 100 person-years; 95% CI: 4.3-7.7) during a 4-month follow-up, resulting in a relative efficacy of 51.7% (95% CI, 30.9-66.2%) (p < .001) in an intention-to-treat analysis. The RQ3013 vaccine was also found to be significantly more immunogenic against omicron BA.5 compared to the ZF2001 vaccine. Moderate, transient adverse reaction after vaccination occurred more frequently in the RQ3013 group than in the ZF2001 group. Serious adverse events (SAEs) were rare and occurred almost equally in two groups. All SAEs were not related to the vaccination. These findings suggest that a chimeric mRNA vaccine design involving multiple antigenic epitopes provides broader protection across subvariants and variants of SARS-CoV-2 than the subunit vaccine ZF2001.
2 个 Figure · 2 个 KM 面板
Figure 2a. Efficacy of RQ3013 vs . COVID-19 in the mITT population.
Figure 2a · Panel Figure_2a
Panel Figure_2a 是同一 Figure 2a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2b. Efficacy of RQ3013 vs . COVID-19 in the per-protocol population.
Figure 2b · Panel Relative_Efficacy
Panel Relative_Efficacy 是同一 Figure 2b 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。